GT
ENTA icon

Glenmede Trust’s Enanta Pharmaceuticals ENTA Stock Holding History

Glenmede Trust’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-440
Closed -$20K – 1528
2020
Q3 		$20K Buy
440
+20
+5% +$969 ﹤0.01% 1621
2020
Q2 		$21K Buy
420
+306
+268% +$15.8K ﹤0.01% 1569
2020
Q1 		$7K Hold
114
– – ﹤0.01% 2559
2019
Q4 		$7K Sell
114
-66
-37% -$4.09K ﹤0.01% 2559
2019
Q3 		$9 Buy
180
+7
+4% +$520 ﹤0.01% 2393
2019
Q2 		$13 Buy
173
+116
+204% +$10.4K ﹤0.01% 2260
2019
Q1 		$5 Hold
57
– – ﹤0.01% 2603
2018
Q4 		$4 Buy
+57
New +$4.37K ﹤0.01% 2596
2016
Q3 		– Sell
-1,000
Closed -$22K – 2604
2016
Q2 		$22K Hold
1,000
– – ﹤0.01% 1866
2016
Q1 		$29K Hold
1,000
– – ﹤0.01% 1691
2015
Q4 		$33K Sell
1,000
-19,200
-95% -$626K ﹤0.01% 1706
2015
Q3 		$729K Buy
20,200
+19,200
+1,920% +$824K 0.01% 798
2015
Q2 		$44K Hold
1,000
– – ﹤0.01% 1674
2015
Q1 		$30K Sell
1,000
-407,476
-100% -$15.9M ﹤0.01% 1830
2014
Q4 		$20.8M Buy
408,476
+80,821
+25% +$3.62M 0.16% 199
2014
Q3 		$13M Buy
327,655
+102,486
+46% +$4.09M 0.11% 267
2014
Q2 		$9.7M Buy
225,169
+224,169
+22,417% +$8.55M 0.09% 311
2014
Q1 		$39K Hold
1,000
– – ﹤0.01% 1713
2013
Q4 		$27K Hold
1,000
– – ﹤0.01% 1771
2013
Q3 		$22K Hold
1,000
– – ﹤0.01% 1784
2013
Q2 		$17K Buy
+1,000
New +$19.5K ﹤0.01% 1761

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Glenmede Trust's ENTA Position: Q4 2020 in Review

Glenmede Trust sold out of Enanta Pharmaceuticals (ENTA) in Q4 2020, closing a stake of 440 shares — an estimated $20K sold.

Glenmede Trust first reported a position in ENTA in Q2 2013 and held it in 21 quarters. The position peaked at $20.8M in Q4 2014. 151 funds tracked by Wall St. Rank hold ENTA as of Q4 2020.

  • Glenmede Trust reported no remaining Enanta Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 440 Enanta Pharmaceuticals shares in Q4 2020, an estimated $20K.
  • Glenmede Trust first reported a position in Enanta Pharmaceuticals in Q2 2013 and held it in 21 quarters.
  • Glenmede Trust's Enanta Pharmaceuticals position peaked at $20.8M in Q4 2014.
  • 151 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.